

**STATE OF FLORIDA  
DIVISION OF ADMINISTRATIVE HEARINGS**

AIDS HEALTHCARE FOUNDATION, INC.,  
and RECIPIENT ONE,

Petitioners,

vs.

DOAH Case No. \_\_\_\_\_

FLORIDA DEPARTMENT OF HEALTH,

Respondent.

/

**PETITION CHALLENGING AGENCY STATEMENTS AS  
UNPROMULGATED RULES AND REQUEST FOR EXPEDITED HEARING**

Petitioners, AIDS Healthcare Foundation, Inc. (“AHF”) and Recipient One (“Petitioners”), petition the Division of Administrative Hearings for an administrative determination that statements by the Florida Department of Health (“Respondent” or “Department”) constitute invalid, unenforceable, and unpromulgated rules. The Department has issued letters to multiple patients who are recipients of medication and health care premium insurance support under the grant program provided by the United States Health and Human Services Ryan White Part B AIDS Drug Assistance Program (“ADAP”) and administered through the Department, indicating that these patients will no longer receive these life-saving services as of March 1, 2026. The Department has issued statements of general applicability without engaging in the mandatory rulemaking process required under Florida’s Administrative Procedure Act. Petitioners seek relief pursuant to sections 120.56(1) and 120.56(4), Florida Statutes. Support for this Petition follows:

## **I. THE PARTIES**

1. The agency affected by this proceeding is the Department of Health, and its principal place of business is 4052 Bald Cypress Way, Tallahassee, Florida 32399, telephone number (850)245-4444.

2. AHF is a Foreign Not-For-Profit Corporation authorized to do business in Florida. AHF's principal address is 700 SE Third Ave., Fourth Floor, Fort Lauderdale, Florida 33316.

3. Recipient One is a Florida resident currently receiving medication and insurance premium assistance benefits from ADAP. Recipient One's address is confidential.

4. For the purposes of this proceeding, AHF's and Recipient One's contact information is that of the undersigned counsel.

5. AHF is the largest non-profit HIV/AIDS organization in the world, providing health care services to more than 2.7 million individuals. AHF provides services to patients eligible for and receiving ADAP services in Florida, through contracts throughout the state. AHF holds a total of 16 contracts with the Department to provide clinical services to patients at risk for HIV infection and patients diagnosed with HIV or AIDS in Florida; four of these are Part B contracts.

## **II. FACTUAL AND PROCEDURAL HISTORY**

6. The Ryan White HIV/AIDS Program ("RWHAP") is housed within the Federal Health Resources & Services Administration ("HRSA"), an agency within the U.S. Department of Health and Human Services ("HHS"). Since 1990, the program

has provided grants to states to pay for medical and support services for low-income people living with HIV. More than 50% of people diagnosed with HIV receive assistance from RWHAP each year.

7. Without proper care and treatment, AIDS is a terminal disease. Every year, thousands of Americans die from HIV/AIDS. With proper care and treatment, including access to expensive antiretroviral medications and regular health care, AIDS is a chronic but manageable disease.

8. ADAP, provided through RWHAP Part B, provides FDA-approved medications, including antiretroviral treatments, medications for opportunistic infections, and drugs for hepatitis B/C, to individuals living with HIV/AIDS. These medications turn HIV/AIDS from a fatal disease into a manageable condition. Removing or interrupting any part of that system can lead to viral rebound, drug resistance, hospitalization, and death.

9. Currently, one of the medications available under the ADAP formulary is Biktarvy, a widely recommended full HIV/AIDS treatment regimen in one pill. Biktarvy has become the gold standard first-line therapy because it combines a high barrier to resistance, good tolerability, and the simplicity of one pill per day, which supports patient medication adherence.

10. Another widely used medication currently available to all patients under ADAP is Descovy. Descovy is not a full HIV/AIDS regimen like Biktarvy, and must be used in combination with other antiretroviral agents for treating HIV/AIDS.

However, Descovy replaced an older HIV/AIDS medication due to its lower risk of kidney toxicity and bone density.

11. Removing an individual's access to Biktarvy/Descovy can result in serious consequences, such as high risk of poor adherence and viral rebound, reduced clinical ability to provide optimal care, psychological harm to patients, and broader public health risks due to potential increases in HIV transmission. Restricting drug options also forces clinicians to prescribe older or less optimal medications for reasons not driven by clinical need.

12. ADAP also provides health insurance premium support (allowing eligible patients to purchase health insurance) to eligible individuals living with HIV. This is not a peripheral benefit, but the primary mechanism through which many people with HIV/AIDS obtain uninterrupted access to antiretroviral therapy and the medical care necessary to stay alive. Modern HIV treatment requires continuous access to a complex and expensive combination of antiretroviral medications, laboratory monitoring, and physician care. ADAP's health insurance premium support allows patients to purchase that access by paying insurance premiums for individuals living with HIV/AIDS who otherwise would not be able to afford this life-saving care and treatment. HIV/AIDS infection also correlates and has comorbidities with a number of other physical and mental health issues, and insurance premium support helps to provide whole-person care and coverage for all conditions affecting these patients.

13. Restricting health insurance premium assistance and medication access will lead to treatment interruptions, medical crisis, and preventable deaths for many

individuals currently receiving such assistance. These outcomes directly contradict the purpose of ADAP and the RWHAP.

14. In fiscal year 2024, RWHAP awarded \$84,895,726.00 to Florida for the administration of ADAP; Florida's total fiscal year 2024 RWHAP Part B funding was \$134,661.497.00.

15. The Department is the state agency tasked with conducting communicable disease prevention and control programs for the prevention and control of HIV and AIDS under chapters 381 and 384. § 381.003(1)(b), Fla. Stat. The Department receives RWHAP Part B grant funding as part of this core public health mission that it has been tasked to administer by the Florida Legislature.

16. Florida is tasked, under the Public Health Service Act,<sup>1</sup> with defining “low-income” individuals to be eligible for ADAP benefits.

17. In 2007, the Department promulgated rules relating to ADAP eligibility in Florida Administrative Code Chapter 64D-4. Since October 27, 2008, the Department has defined “low income” to be adjusted gross household income<sup>2</sup> “at or below 400 percent of the Federal Poverty Level.” R. 64D-4.002(6), Fla. Admin. Code (eff. 10-12-22).

18. The same rules define “HIV/AID Patient Care Programs” to include the “Ryan White Part B AIDS Drug Assistance Program, a program that provides medications to uninsured or underinsured individuals living with HIV/AIDS disease.”

---

<sup>1</sup> 42 U.S.C. § 300ff-26(b).

<sup>2</sup> The word “adjusted” appears before gross household income in the currently-effective version of the rule, but did not appear in the October 2008 version.

It indicates that such services are provided through the distribution of medications directly to eligible clients or by the purchase of health insurance that includes coverage for HIV/AIDS medications.

19. To be eligible for ADAP, the premium assistance program, and the HIV/AIDS patient care program service, an individual must (1) have a positive HIV test, (2) be living in Florida, (3) not be receiving the same services or be eligible to receive the same services through another program, (4) **must have low income** as defined by rule, (5) must submit a completed application and cooperate with the eligibility process and abide by the program requirements, and (6) must have their eligibility confirmed every 366 days (or sooner if their income or other factors change).

R. 64D-4.003, Fla. Admin. Code (eff. 10-12-22).

### **III. THE DEPARTMENT'S UNPROMULGATED RULES**

20. In January 2026, the Department began issuing at least two versions of letters to patients currently benefitting from the Department's administration of ADAP. One version of the letter (**Exhibit A**) indicates that the patient will no longer receive premium insurance support and medication services through ADAP as of February 28, 2026, and the second (**Exhibit B**) indicates that the patient remains eligible for direct medication services through ADAP, but notifies them that if they are currently taking Biktarvy, they must contact their health care provider to receive a prescription for a clinically equivalent medication because Biktarvy will no longer be offered. Both letters note that the Department will only provide funding to patients if their income is at or below 130% of the Federal Poverty Level.

Additionally, the Department’s webpage notes that ADAP will only cover costs of HIV medications directly for individuals at or below 130% of the Federal Poverty Level (**Exhibit C**).<sup>3</sup>

21. Recipient One is an individual currently receiving the benefits provided through ADAP for health insurance premium and medication coverage. Recipient One will lose this coverage based upon the Department’s unadopted rules.

22. The National Alliance of State and Territorial AIDS Directors (“NASTAD”) estimates that more than 16,000 patients in Florida will lose ADAP coverage because of this change in Department policy. AHF provides services through ADAP to a number of these patients who will lose their ability to pay health insurance premiums, impacting all aspects of their physical and mental wellbeing, and a number of patients who will no longer be able to access life-saving medications.

23. The letters issued to ADAP recipients in Florida, as well as the Department’s public-facing messaging, including that of its webpage and of the State Surgeon General, describe eligibility restrictions that differ from those set forth in the governing rules, and remove life-saving medications from the Florida ADAP formulary (attached as **Exhibit D**). The various rules governing the Department’s administration of the ADAP program have not been modified through the mandatory rulemaking process.

24. The Department has declared that individuals who are currently eligible for ADAP services between 130% and 400% of the Federal Poverty Level will not be

---

<sup>3</sup> <https://www.floridahealth.gov/individual-family-health/injury-prevention-wellness/hiv-aids/hiv-aids-management/> (Last visited January 25, 2026).

eligible for any ADAP medication services, that individuals receiving insurance premium assistance services will no longer be eligible for those services beginning on March 1, 2026, and even those individuals remaining eligible for the Department's ADAP benefits will be subject to reduced and restricted access to ADAP approved medications. However, the Department has not modified the existing rule to redefine "low income."

25. Further, the Department has removed Biktarvy from the ADAP formulary and has indicated that Descovy will now only be available to patients with renal insufficiency. However, Department has not made these changes to the HIV/AIDS patient care program through the mandatory rulemaking process.

26. An unpromulgated rule is any "statement of general applicability that implements, interprets, or prescribes law or policy or describes the organization, procedure, or practice requirements of an agency" and has not been properly promulgated in conformance with section 120.54, Florida Statutes. *Dep't of Revenue v. Vanjara Enters., Inc.*, 675 So. 2d 252, 255 (Fla. 5th DCA 1996) (internal citations omitted). This includes any such statement which "imposes any requirement" on a regulated party beyond what is promulgated. *Id.*; see also *State Bd. of Admin. v. Huberty*, 46 So. 3d 1144, 1147 (Fla. 1st DCA 2010). While an agency statement that merely reiterates a law or restates what is readily apparent from the text of a law may not be considered a rule, "[a]n agency statement or policy is a rule if its effect requires compliance, creates certain rights while adversely affecting others, or otherwise has the direct and consistent effect of law." *Dep't of Health v. Leafly*

*Holdings, Inc.*, 369 So. 3d 333 (quoting *Jenkins v. State*, 855 So.2d 1219, 1225 (Fla. 1st DCA 2003)); *St. Francis Hosp., Inc. v. Dep't of Health and Rehab. Servs.*, 553 So.2d 1351, 1354 (1st DCA. 1989).

27. The focus in determining whether an agency statement is a rule within the meaning of section 120.52(16), Florida Statutes, is on the effect of the statement rather than the agency's characterization of it. *Dep't of Rev. v. Vanjaria Enters., Inc.*, 675 So. 2d 252, 255 (Fla. 5th DCA 1996); *Balsam v. Dep't of HRS*, 452 So. 2d 976, 977 (Fla. 1st DCA 1984); *Amos v. Dep't of HRS*, 444 So. 2d 43, 46-47 (Fla. 1st DCA 1983); *State Dep't of Admin. v. Harvey*, 356 So. 2d 323, 325 (Fla. 1st DCA 1977).

28. A statement is not generally applicable if it is applied solely on a case-by-case basis. *Agency for Health Care Admin. v. Custom Mobility, Inc.*, 995 So. 2d 984, 986 (Fla. 1st DCA 2008). However, a statement need not apply to every party in a given field to meet this requirement. *Dep't of Highway Safety & Motor Vehicles v. Schluter*, 705 So. 2d 81, 83 (Fla. 1st DCA 1997).

29. Policies that apply only to specific subgroups have been determined to meet the definition of a rule and, therefore, be generally applicable. *Harvey*, 356 So. 2d at 323 (statement applied only to career-service state employees, not state employees as a whole); *Schluter*, 705 So. 2d at 83 (applied to all policemen under investigation, not police as a whole); *Williams v. Dep't of Highway Safety & Motor Vehicles*, DOAH Case No. 16-6127RU (Fla. DOAH Mar. 3, 2017) (applied to all vehicles coming into Florida from a foreign country, not vehicles as a whole). Such is

the case when a policy applies “uniformly to a class of persons or activities over which the [agency] exercises authority.” *Williams*, DOAH Case No. 16-6127RU, ¶ 41.

30. Rulemaking is not a matter of agency discretion. § 120.54(1)(a), Fla. Stat. Each agency statement that meets the statutory definition of a rule must be adopted through rulemaking procedures as soon as feasible and practicable. § 120.54(1)(a), Fla. Stat.

31. A rule is defined in the Florida Administrative Procedure Act as:

(16) “Rule” means each agency statement of general applicability that implements, interprets, or prescribes law or policy or describes the procedure or practice requirements of an agency and includes any form which imposes any requirement or solicits any information not specifically required by statute or by an existing rule. The term also includes the amendment or repeal of a rule. The term does not include:

(a) Internal management memoranda which do not affect either the private interests of any person or any plan or procedure important to the public and which have no application outside the agency issuing the memorandum.

(b) Legal memoranda or opinions issued to an agency by the Attorney General or agency legal opinions prior to their use in connection with an agency action.

(c) The preparation or modification of:

1. Agency budgets.

2. Statements, memoranda, or instructions to state agencies issued by the Chief Financial Officer or Comptroller as chief fiscal officer of the state and relating or pertaining to claims for payment submitted by state agencies to the Chief Financial Officer or Comptroller.

3. Contractual provisions reached as a result of collective bargaining.

4. Memoranda issued by the Executive Office of the Governor relating to information resources management.

§ 120.52(16), Fla. Stat. (2025).

32. The policy announced by the Department through its statements, webpage, and letters to ADAP recipients constitutes statements of general applicability that change existing eligibility requirements under Florida Administrative Code Chapter 64D-4. It does not meet the definition of any exceptions to what constitutes a rule in Florida law.

33. The Department has failed to promulgate this new policy as a rule, and it therefore violates section 120.54(1)(a) because it has not been adopted by rule.

### **III. PETITIONERS' SUBSTANTIAL INTERESTS ARE AFFECTED**

34. Under Florida law, “[a]ny person substantially affected by an agency statement that is an unadopted rule may seek an administrative determination that the statement violates s. 120.54(1)(a).” § 120.56(4)(a), Fla. Stat. The fact that a party will be regulated by a rule at issue in an administrative proceeding is “alone sufficient to establish that their substantial interests will be affected.” *Reiff v. Ne. Fla. State. Hosp.*, 710 So. 2d 1030, 1032 (Fla. 1st DCA 1998) (quoting *Coalition of Mental Health Professions v. Dep’t of Prof'l Reg.*, 546 So. 2d 27 (Fla. 1st DCA 1989)).

35. AHF administers RWHAP Part B benefits to eligible HIV/AIDS patients in Florida through both contracts with the Department and other municipalities. The Department’s modified policy substantially affects AHF’s ability to comply with the requirements of these agreements, including providing services to patients eligible to receive them under current Florida law. Thus, AHF’s interests are substantially affected by the Department’s new and modified policy.

36. Recipient One is a beneficiary of RWHAP Part B/ADAP. The Department's unadopted policy substantially affects Recipient One in that he will no longer be able to obtain medications approved or health insurance premium support based on the stated policy that will be in effect March 1, 2026.

#### **IV. DISPUTED ISSUES OF MATERIAL FACT**

37. Disputed issues of material fact include, but are not limited to:
- a. Whether the Department's statements modifying the maximum percentage of Federal Poverty Levels for ADAP medication and premium assistance eligibility constitute an unadopted rule;
  - b. Whether the Department's intended action to remove ADAP medication and premium assistance coverage for currently-eligible patients, and modify and further restrict medication access for eligible patients, is pursuant to an unadopted rule; and
  - c. Whether the Department should be prohibited from relying on the unadopted rule.
  - d. Whether the Department's statements modifying the ADAP formulary constitute an unadopted rule;
  - e. Whether the Department's intended action to remove Biktarvy and modify Descovy coverage for currently-eligible patients is pursuant to an unadopted rule; and
  - f. Whether the Department should be prohibited from relying on the unadopted rule.

**V. CONCISE STATEMENT OF ULTIMATE FACTS ALLEGED**

38. The Department's modification of patient eligibility for ADAP benefits from 400% of the Federal Poverty Level to 130% of the Federal Poverty Level constitutes an unadopted rule in violation of section 120.54(1).

39. The Department's removal of patient eligibility for ADAP insurance premium assistance constitutes an unadopted rule in violation of section 120.54(1).

40. The Department's modification of the ADAP drug formulary to remove Biktarvy and restrict Descovy constitutes an unadopted rule in violation of section 120.54(1).

41. The Department's removal of patient eligibility for certain drugs under the HIV/AIDS patient care program constitutes an unadopted rule in violation of section 120.54(1).

**VI. RULES OR STATUTES REQUIRING MODIFICATION OF AGENCY ACTION**

42. Specific statutes and rules requiring modification of the Department's actions include, but are not limited to, sections 120.52, 120.54, 120.56, 381.0011, and 381.003, Florida Statutes, and Chapter 64D-4, Florida Administrative Code.

**VII. RESERVATION OF RIGHT TO AMEND**

43. AHF has pending public records requests with the Department that remain unfulfilled. Therefore, AHF reserves the right to amend this petition as additional facts become known through the review of documents received in response to public records requests and discovery conducted in this case.

### **VIII. REQUEST FOR EXPEDITED HEARING**

44. Because approximately 16,000 individuals in Florida stand to lose their life-saving ADAP benefits and will be left without viable alternatives to live healthy lives and prevent additional spread of HIV as of March 1, 2026, the standard timeframe of 30 days for the hearing to commence and 30 days to render a Final Order provided in section 120.56 is direly inadequate.

45. The Department has brought this emergency to patients on itself, and AHF respectfully requests an expedited scheduling order for discovery, final hearing, and Final Order be considered. AHF recommends five days for discovery, 14 days for a hearing, and 14 days for a Final Order.

### **IX. ENTITLEMENT TO ATTORNEY'S FEES**

46. Section 120.595(4) provides that, if the Administrative Law Judge determines that any statement by the Department alleged herein constitutes an unadopted rule, or that the Department must immediately discontinue reliance on the statement, an "...order shall be entered against the agency for reasonable costs and reasonable attorney's fees...." No exception applies. As a result, should any Petitioner prevail in this matter, Petitioners respectfully request the award of reasonable costs and reasonable attorney's fees.

### **X. RELIEF REQUESTED**

WHEREFORE, based upon the foregoing, AHF respectfully requests that:

- a. A formal administrative hearing pursuant to sections 120.569 and 120.57(1) be held in an expedited manner;

- b. A Final Order be entered determining that the Department's policy set forth in the letters to patients and in public-facing statements constitutes an unadopted rule and violates section 120.54(1)(a); and ordering the Department to immediately discontinue all reliance upon the unadopted rule or any substantially similar statement;
- c. An award of reasonable costs and reasonable attorney's fees be entered; and
- d. Grant any other relief as may be deemed just, appropriate, or necessary.

Respectfully submitted,

/s/Louise Wilhite-St Laurent  
LOUISE WILHITE-ST LAURENT  
[LStLaurent@panzamaurer.com](mailto:LStLaurent@panzamaurer.com)  
Florida Bar No.: 91244  
SAMANTHA EVANS SALTZBURG  
[SEvans@panzamaurer.com](mailto:SEvans@panzamaurer.com)  
Florida Bar No.: 124088  
Panza, Maurer & Maynard, P.A.  
201 East Park Avenue, Suite 200A  
Tallahassee, FL 32301  
Tel: (850) 681-0980

ATTORNEYS FOR PETITIONERS

**CERTIFICATE OF SERVICE**

I HEREBY CERTIFY that on January 27, 2026, the foregoing has been e-filed with the Division of Administrative Hearings and a copy furnished to the following via e-mail:

Alysson Bradley  
Interim General Counsel  
Florida Department of Health  
4052 Bald Cypress Way, Bin A-02  
Tallahassee, Florida 32399  
[Alysson.Bradley@flhealth.gov](mailto:Alysson.Bradley@flhealth.gov)

*/s/Louise Wilhite-St Laurent*  
LOUISE WILHITE-ST LAURENT

EXHIBIT A

TO UNPROMULGATED RULE

CHALLENGE

You are receiving the following information as you have been identified as a client that is currently receiving premium insurance support and medication services through the U.S. Health and Human Services grant program known as the Ryan White Part B Drug Assistance Program (ADAP).

Due to the increase in the cost of HIV/AIDS medication and health insurance premiums, eligibility criteria for current Ryan White Part B ADAP clients will change.

The federal funding limitation requires an adjustment to the services provided by the ADAP Patient Care Program and reassessment of clients that will be served by the Ryan White Part B ADAP. Effective March 1, 2026, ADAP Patient Care services will no longer be offering the ADAP Premium Plus Insurance Program. ADAP Patient Care services will be limited to providing medication services through the Ryan White Part B ADAP.

Records indicate that, as of March 1, 2026, you will no longer be eligible to receive health insurance and direct medication services through the Ryan White Part B ADAP. Based on our records, your insurance coverage will end on February 28, 2026.

Eligibility for receiving direct medication assistance through the Ryan White Part B ADAP program will be prioritized based on the Federal Poverty Level of up to 130%. For any questions regarding the direct medication services eligibility, please contact Prime Therapeutics, LLC., at 1-833-604-0925.

Clients who are no longer serviced by the Ryan White Part B ADAP can seek alternative services through the following resources:


- **NASTAD Pharmaceutical Assistance Resources:**  
<https://nastad.org/resources/pharmaceutical-company-patient-assistance-programs-and-cost-sharing-assistance-programs>
- **Florida Medicaid:** <https://myaccess.myflfamilies.com/Public/login>
- **Medicare:** <https://www.cms.gov/medicare/enrollment-renewal/original-part-a-b>

Please contact the ADAP Help Desk at 844-381-2327 with any questions.



EXHIBIT B

TO UNPROMULGATED RULE  
CHALLENGE



You are receiving the following information as you have been identified as a client that is currently receiving direct medication services through the U.S. Health and Human Services grant program known as the Ryan White Part B Drug Assistance Program (ADAP).

Due to the increase in the cost of HIV/AIDS medication and health insurance premiums, eligibility criteria for current ADAP clients will change.

Under current federal funding limitations, clients that are serviced by the Ryan White Part B ADAP will be prioritized based on the Federal Poverty Level up to 130% effective March 1, 2026. In addition, Biktarvy will no longer be available on the ADAP formulary as a medication option for Ryan White Part B ADAP clients receiving direct medication assistance, however, clinically equivalent medications will still be available.

Records indicate you are eligible to continue receiving direct medication services through the Ryan White Part B ADAP. Additionally, if you are currently taking Biktarvy, please contact your health care provider to receive a prescription for a clinically equivalent medication.

Please contact the ADAP Help Desk at 844-381-2327 with any questions regarding these changes and to coordinate any medication changes that will be required.



**Vision:**

To be the **Healthiest State** in the Nation



**Accredited Health Department**  
Public Health Accreditation Board



EXHIBIT C

TO UNPROMULGATED RULE  
CHALLENGE

# AIDS DRUG ASSISTANCE PROGRAM

## UPDATES TO ADAP

Due to rising health care insurance premiums nationwide and lack of additional Ryan White Grant funding, adjustments have been made to ensure resources the greatest number of individuals within our funding constraints.

The Department remains committed to delivering services through this vital program and will instead cover the costs of HIV medications directly for individuals at or below 130% of the **Federal Poverty Level**. The Department will also cover costs during a two-month transition period to ensure clients have adequate time to connect to services if they are impacted by these changes. These adjustments will prevent a shortfall of more than \$120 million for Florida.

We encourage those in need to connect with available community resources to help with connection to care:

### PATIENT ASSISTANCE PROGRAMS

- [National Alliance of State and Territorial AIDS Directors \(NASTAD\)](#)
- [Pharmaceutical Companies Patient Assistance Programs and Cost-Sharing Assistance Programs](#)
- [Patient Advocate Foundation Co-Pay Relief](#)
- [HarborPath Non-Profit Assistance](#)

### COMMUNITY, STATE, AND FEDERAL RESOURCES

- [Florida Association of Community Health Centers](#)
- [Florida Non-Profit HIV/AIDS Organizations](#)
- [Florida Medicaid](#)
- [Medicare \(individuals age 65 and older\)](#)
- [Medication Discounts](#)

- [Medicine Assistance Tool](#)
- [U.S. Department of Veteran Affairs](#)

The AIDS Drug Assistance Program (ADAP) is a statewide, federally-funded prescription medication program for low-income people living with HIV. This program provides access to medications to eligible clients either directly or by purchase of health insurance that includes coverage for HIV medications.

**STEP 1: Eligibility and Verification**

**STEP 2: Enrollment**

**STEP 3: Getting Prescriptions Filled**

**SAME DAY Program**

**ADAP Insurance**

**Quarterly Reports**

**Program Assistance**

**ADAP Medication ADAP Formulary Workgroup**

## Prevention & Wellness

Chronic Disease Prevention & Management

Eating Healthy Seafood

Food Access

Healthy Aging, Healthy Brain

## HIV/AIDS

### **AIDS Drug Assistance Program**

Community Programs

Florida Comprehensive Planning Network

Housing Opportunities for Persons With AIDS

Linkage to Care

Planning and Program Administration

Prevention

Human Trafficking

Injury Prevention

Preventing Mosquito and Tick Bites

Sexual Violence

Substance Use & Overdose Prevention

Suicide Prevention

Tobacco Free Florida

## AIDS DRUG ASSISTANCE PROGRAM

**844-381-2327**

Monday-Friday

8 a.m. – 5 p.m.



Led by the State Surgeon General, the mission of the Florida Department of Health is to protect, promote, and improve the health of all people in Florida through integrated state, county, and community efforts.

## ABOUT FLORIDA HEALTH

→ Leadership

→ Agency Organization

→ Careers with Florida Health

→ Contact Us

## RESOURCES

→ Public Records Requests

→ Public Meeting Notices

→ Public Notices

→ Boards, Councils, and Committees

ACCESSIBILITY

ACCREDITATION

DISCLAIMER

ELECTRONIC  
COMMUNICATION

PRIVACY POLICY

SITE MAP



EXHIBIT D

TO UNPROMULGATED RULE

CHALLENGE

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*

CS indicates controlled substance. <sup>PA</sup> indicates prior authorization required.

Generic Name	Brand Name (listed for Antiretroviral drugs only)	Therapeutic Classification	Pharmacologic Classification
abacavir	Ziagen	Antiretroviral	NRTI
abacavir / lamivudine	Epzicom	Antiretroviral	NRTI combo
abacavir / dolutegravir / lamivudine	Triumeq	Antiretroviral	INSTI/NRTI combo
atazanavir	Reyataz	Antiretroviral	PI
atazanavir/cobicistat	Evotaz	Antiretroviral	PI/PK Enhancer
bictegravir / emtricitabine / tenofovir alafenamide	Biktarvy	Antiretroviral	INSTI/NRTI combo
cabotegravir	Vocabria	Antiretroviral	INSTI
cabotegravir / rilpivirine	Cabenuva	Antiretroviral	INSTI/NNRTI combo
cobicistat	Tybost	Antiretroviral	PK Enhancer
darunavir	Prezista	Antiretroviral	PI
darunavir / cobicistat	Prezcobix	Antiretroviral	PI/PK Enhancer
darunavir / cobicistat / emtricitabine / tenofovir alafenamide	Syntuza	Antiretroviral	PI/NRTI combo
dolutegravir	Tivicay	Antiretroviral	INSTI
dolutegravir / lamivudine	Dovato	Antiretroviral	INSTI/NRTI combo
dolutegravir / rilpivirine	Juluca	Antiretroviral	INSTI/NNRTI combo
doravirine	Pifelro	Antiretroviral	NNRTI
doravirine / lamivudine / tenofovir disoproxil fumarate	Delstrigo	Antiretroviral	NNRTI/NRTI combo
efavirenz	Sustiva	Antiretroviral	NNRTI
efavirenz / emtricitabine / tenofovir disoproxil fumarate	N/A	Antiretroviral	NNRTI/NRTI combo
efavirenz / lamivudine / tenofovir disoproxil fumarate	Symfi, SymfiLo	Antiretroviral	NNRTI/NRTI combo
elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide	Genvoya	Antiretroviral	INSTI/NRTI combo
elvitegravir / cobicistat / emtricitabine /tenofovir disoproxil fumarate	Stribild	Antiretroviral	INSTI/NRTI combo
emtricitabine	Emtriva	Antiretroviral	NRTI
emtricitabine / tenofovir alafenamide	Descovy	Antiretroviral	NRTI combo
emtricitabine / tenofovir disoproxil fumarate	Truvada	Antiretroviral	NRTI combo
enfuvirtide	Fuzeon	Antiretroviral	Fusion inhibitor
etravirine	Intelence	Antiretroviral	NNRTI
fostemsavir	Rukobia	Antiretroviral	Gp-120 directed attachment inhibitor
Ibalizumab-uiyk injection <sup>PA</sup>	Trogarzo <sup>PA</sup>	Antiretroviral	CD4 post-attachment HIV-1 inhibitor
lamivudine	Epivir	Antiretroviral	NRTI
lamivudine / zidovudine	Combivir	Antiretroviral	NRTI combo
lenacapavir	Sunlenca	Antiretroviral	Capsid inhibitor
lopinavir / ritonavir	Kaletra	Antiretroviral	PI/PK Enhancer
maraviroc	Selzentry	Antiretroviral	CCR5 antagonist
nevirapine, nevirapine XR	Viramune, Viramune XR	Antiretroviral	NNRTI
raltegravir, raltegravir HD	Isentress, Isentress HD	Antiretroviral	INSTI
rilpivirine	Edurant	Antiretroviral	NNRTI
rilpivirine / emtricitabine/ tenofovir disoproxil fumarate	Complera	Antiretroviral	NNRTI/NRTI combo
rilpivirine / emtricitabine / tenofovir alafenamide	Odefsey	Antiretroviral	NNRTI/NRTI combo
ritonavir	Norvir	Antiretroviral	PK Enhancer
tenofovir alafenamide	Vemlidy	Antiretroviral	NRTI
tenofovir disoproxil fumarate	Viread	Antiretroviral	NRTI

tenofovir disoproxil fumarate / lamivudine	Cimduo, Temixys	Antiretroviral	NRTI combo
zidovudine	Retrovir	Antiretroviral	NRTI
<b>Florida AIDS Drug Assistance Program (ADAP) Formulary</b>			<b>September 2024</b>
****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****			
CS indicates controlled substance. PA indicates prior authorization required.			
Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
acetaminophen	Analgesic	Non-salicylate analgesic	capsule, tablet, oral liquid, rectal suppository
acetaminophen/hydrocodone <sup>CS</sup>	Analgesic	Nonsalicylate/opioid	capsule, tablet, oral liquid
acetaminophen/oxycodone <sup>CS</sup>	Analgesic	Nonsalicylate/opioid	tablet, oral liquid
acetazolamide	Antiglaucoma	Carbonic anhydrase inhibitor	capsule, tablet
acyclovir	Anti-infective	Antiviral	capsule, tablet, oral liquid, topical
albuterol	Respiratory	Beta-2 Agonist	inhaler, nebulizer solution, tablet, oral liquid
albuterol HFA	Respiratory	Beta-2 Agonist	inhaler
albuterol/ipratropium	Respiratory	Anticholinergic + Beta-2 Agonist, oral inhaled	inhaler, nebulizer solution
alendronate	Osteoporosis	Bisphosphonate	tablet, oral liquid
alirocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
allopurinol	Antigout	Xanthine oxidase inhibitor	tablet
amitriptyline	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	tablet
amlodipine	Cardiovascular	Calcium channel blocker	tablet, oral liquid
amlodipine/atorvastatin	Cardiovascular	Calcium channel blocker/HMG-CoA reductase inhibitor	tablet
amlodipine/benazepril	Cardiovascular	Calcium channel blocker/ACE inhibitor	capsule
amlodipine/olmesartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
amlodipine/valsartan	Cardiovascular, antihypertensive	Calcium channel blocker/angiotensin II receptor blocker	tablet
ammonium lactate	Dermatologic	Humectant	topical
amoxicillin	Anti-infective	Beta-lactam antibiotic	capsule, tablet, oral liquid
amoxicillin/clavulanate	Anti-infective	Beta-lactam antibiotic/beta-lactamase inhibitor	tablet, oral liquid
amphetamine/dextroamphetamine <sup>CS</sup>	Central nervous system	ADHD agent, stimulant	tablet, capsule
apixaban	Blood formation and coagulation	Anticoagulant	tablet
ariPIPrazole	Central nervous system	Antipsychotic, atypical	tablet, injection
aspirin	Analgesic	Salicylate	caplet, tablet, rectal suppository
atenolol	Cardiovascular	Beta-blocker	tablet
atenolol/chlorthalidone	Cardiovascular	Beta-blocker/thiazide-like diuretic	tablet
atomoxetine	Central nervous system	ADHD agent, non-stimulant	capsule
atorvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet, oral liquid
atovaquone	Anti-infective	Amebicide	oral liquid
azelastine	Respiratory	Antihistamine	nasal spray, eye drops
azelastine/fluticasone	Respiratory	Antihistamine/corticosteroid, intranasal	nasal spray
azithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid, eye drops
baclofen	Central nervous system	Muscle relaxant	tablet, oral liquid
baloxavir	Anti-infective	Anti-influenza antiviral	tablet, oral liquid
beclomethasone	Respiratory	Corticosteroid	nasal spray, inhaler
bempedoic acid	Cardiovascular, antihyperlipidemic	ACL inhibitor	tablet
benazepril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
benazepril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
benzoyl peroxide	Dermatologic	Antibiotic + keratolytic	topical
benzoyl peroxide/clindamycin	Dermatologic	Anti-acne retinoid	topical
benztropine	Central nervous system	Anticholinergic	tablet
betamethasone dipropionate	Dermatologic	Corticosteroid	topical
betamethasone valerate	Dermatologic	Corticosteroid	topical
betamethasone/clotrimazole	Dermatologic	Corticosteroid, antifungal	topical
bisacodyl	Gastrointestinal	Laxative, stimulant	tablet, rectal suppository
bismuth subcitrate potassium/metronidazole/tetracycline	Gastrointestinal	Helicobacter pylori agents	tablets and capsules (therapy kit)
brexpiprazole	Central nervous system	Antipsychotic, atypical	tablet
brimonidine	Antiglaucoma	Alpha-2 agonist	eye drops, eye gel
brimonidine/timolol	Antiglaucoma	Alpha agonist/beta blocker	eye drops
budesonide	Respiratory	Corticosteroid	inhaler, nasal spray
budesonide/formoterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
budesonide/glycopyrrolate/formoterol	Respiratory	Corticosteroid/anticholinergic/long-acting Beta-2 agonist	inhaler
buprenorphine/naloxone <sup>CS</sup>	Substance abuse	Opiate agonist/antagonist	tablet, oral film
buprenorphine <sup>CS</sup>	Substance abuse	Opiate agonist/antagonist	tablet, oral film, patch
bupropion	Central nervous system	Antidepressant-miscellaneous, aminoketone	tablet
buspirone	Central nervous system	Anxiolytic	tablet
calcium carbonate	Vitamin	Vitamin	tablet, oral liquid
calcium with vitamin D	Vitamin	Vitamin	tablet
canagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
canagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
capsaicin	Dermatologic	Analgesic	topical
carbamazepine	Central nervous system	Anti-manic, anti-seizure	tablet, capsule
carbamide peroxide	Otic	Ear wax removal agent	ear drops, oral liquid
carboxymethylcellulose	Ophthalmic	Lubricating agent	eye drops
carvedilol	Cardiovascular	Beta-blocker	capsule, tablet
cefdinir	Anti-infective	Cephalosporin antibiotic	capsule, oral liquid
cefixime	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
ceftriaxone	Anti-infective	Cephalosporin antibiotic	injection
celecoxib	Analgesic	COX-II Inhibitor Non-steroidal anti-inflammatory drug	capsule, oral liquid
cephalexin	Anti-infective	Cephalosporin antibiotic	capsule, tablet, oral liquid
cetirizine	Respiratory	Antihistamine	tablet, oral liquid
chlorhexidine gluconate (0.12%)	Dermatologic	Anti-infective	oral liquid
chlorthalidone	Cardiovascular	Thiazide-like diuretic	tablet
cholecalciferol (vitamin D3)	Vitamin	Vitamin	capsule, tablet, oral liquid
ciprofloxacin	Anti-infective	Quinolone antibiotic	tablet, ear drops, eye drops, oral liquid
ciprofloxacin/dexamethasone	Anti-infective/anti-inflammatory	Quinolone antibiotic/corticosteroid	ear drops
citalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
clarithromycin	Anti-infective	Macrolide antibiotic	tablet, oral liquid
clindamycin	Anti-infective	Lincosamide antibiotic	capsule, oral liquid, topical
clonazepam <sup>CS</sup>	Central nervous system	Benzodiazepine	tablet

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
clonidine	Cardiovascular	Centrally acting alpha 2 agonist	tablet, oral liquid, patch
clopidogrel	Cardiovascular	Platelet inhibitor	tablet
clotrimazole	Anti-infective	Azole antifungal	oral troche, topical
conjugated estrogens (topical only)	Dermatologic	Estrogen	topical
crofelemer	Gastrointestinal	Antidiarrheal	tablet
cyanocobalamin (vitamin B12)	Vitamin	Vitamin	tablet, oral liquid, nasal spray, injection
cyclobenzaprine	Central nervous system	Muscle relaxant	capsule, tablet
cypheptadine	Respiratory	Antihistamine	tablet, oral liquid
dabigatran	Blood formation and coagulation	Anticoagulant	capsule, oral granules
dapagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
dapagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
dapsone	Anti-infective	Sulfone antibiotic	tablet, topical
dexamethasone/neomycin/polymyxin b	Ophthalmic	Corticosteroid/antibacterial	eye drops, eye ointment
dextromethorphan/promethazine	Respiratory	Antitussive/antihistamine	oral liquid
diazepam <sup>CS</sup>	Central nervous system	Benzodiazepine	tablet, oral liquid, nasal spray, rectal gel
diclofenac	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet, eye drops, topical
dicyclomine	Gastrointestinal	Antispasmodic	capsule, tablet, oral liquid
digoxin	Cardiovascular	Cardiac glycoside	tablet, oral liquid
diltiazem	Cardiovascular	Calcium channel blocker	capsule, tablet
diphenhydramine	Respiratory	Antihistamine	capsule, tablet, oral liquid, topical
diphenoxylate/atropine <sup>CS</sup>	Gastrointestinal	Antidiarrheal	tablet, oral liquid
disulfiram	Substance abuse	Alcohol deterrent	tablet
divalproex	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
docusate sodium	Gastrointestinal	Laxative, stool softener	capsule, tablet, oral liquid
donepezil	Central nervous system	Cholinesterase inhibitor	tablet, patch
dorzolamide	Antiglaucoma	Carbonic anhydrase inhibitor	eye drops
dorzolamide/ timolol	Antiglaucoma	Carbonic anhydrase inhibitor, beta-blocker	eye drops
doxazosin	Cardiovascular	Alpha-blocker	tablet
doxepin	Central nervous system	Tricyclic antidepressant (TCA)	capsule, tablet, oral solution, topical
doxycycline	Anti-infective	Tetracycline antibiotic	capsule, tablet, oral liquid
doxylamine/pyridoxine	Gastrointestinal	Anti-nausea agent	tablet
dronabinol <sup>CS</sup>	Gastrointestinal, appetite stimulant	Cannabinoid	capsule, oral liquid
dulaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
duloxetine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule
elbasvir/grazoprevir	Anti-infective	Hepatitis C antiviral	tablet
empagliflozin	Antidiabetic	Sodium-glucose co-transporter 2 (SGLT2) inhibitor	tablet
empagliflozin/metformin	Antidiabetic	SGLT2 inhibitor/biguanide	tablet
enalapril	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet, oral liquid
enalapril/hydrochlorothiazide	Cardiovascular	ACE inhibitor/ thiazide diuretic	tablet
entecavir	Anti-infective	Hepatitis B antiviral	tablet, oral liquid
epoetin alfa	Blood formation and coagulation	Erythropoiesis stimulating agent	injection

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
ergocalciferol (vitamin D2)	Vitamin	Vitamin	capsule, tablet, oral liquid
escitalopram	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	tablet, oral liquid
esomeprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet, oral powder
estradiol	Endocrine	Estrogen	tablet, topical, injection
ethambutol	Anti-infective	Antimycobacterial	tablet
ethinyl estradiol/desogestrel	Endocrine	Estrogen/Progestin	tablet
ethinyl estradiol/etonogestrel	Endocrine	Estrogen/Progestin	vaginal ring
ethinyl estradiol/levonorgestrel	Endocrine	Estrogen/progestin	tablet, patch
ethinyl estradiol/norethindrone	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norethindrone/ferrous fumarate	Endocrine	Estrogen/progestin/iron	tablet
ethinyl estradiol/norgestimate	Endocrine	Estrogen/progestin	tablet
ethinyl estradiol/norgestrel	Endocrine	Estrogen/progestin	tablet
evolocumab	Cardiovascular, antihyperlipidemic	PCSK9 inhibitor	injection
ezetimibe	Cardiovascular, antihyperlipidemic	Cholesterol absorption inhibitor	tablet
ezetimibe/rosuvastatin	Cardiovascular, antihyperlipidemic	Cholinesterase inhibitor/HMG CoA reductase inhibitor	tablet
famciclovir	Anti-infective	Antiviral	tablet
famotidine	Gastrointestinal, acid reducing	Histamine 2 receptor blocker	tablet, oral powder
fenofibrate	Cardiovascular, antihyperlipidemic	Fibric acid derivative	capsule, tablet
ferrous sulfate	Vitamin	Vitamin	tablet, oral liquid
fexofenadine	Respiratory	Antihistamine	tablet, oral liquid
fidaxomicin	Anti-infective	Macrolide antibiotic	tablet, oral powder
filgrastim	Blood formation and coagulation	Granulocyte stimulating agent	injection
finasteride	Genitourinary	5-Alpha Reductase Inhibitor	tablet
fluconazole	Anti-infective	Azole antifungal	tablet, oral liquid
flunisolide (nasal spray)	Respiratory	Corticosteroid, nasal	nasal spray
fluoxetine	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
fluoxetine/olanzapine	Central nervous system	SSRI/atypical antipsychotic, antimanic	capsule
fluticasone	Respiratory	Corticosteroid	inhaler, nasal spray
fluticasone furoate/umeclidinium/vilanterol	Respiratory	Corticosteroid/long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
fluticasone/salmeterol	Respiratory	Corticosteroid + Long acting Beta-2 Agonist, oral inhaled	inhaler
fluticasone/vilanterol	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
folic acid	Vitamin	Vitamin	capsule, tablet
formoterol	Respiratory	Long-acting Beta-2 agonist	inhaler, nebulizer solution
frovatriptan	Central nervous system	Antimigraine	tablet
furosemide	Cardiovascular	Loop diuretic	tablet, oral liquid
gabapentin	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet
gemfibrozil	Cardiovascular, antihyperlipidemic	Fibric acid derivative	tablet
glecaprevir/pibrentasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet
glimepiride	Antidiabetic	Sulfonylurea	tablet
glipizide	Antidiabetic	Sulfonylurea	tablet
glipizide/metformin	Antidiabetic	Sulfonylurea/biguanide	tablet

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
glyburide	Antidiabetic	Sulfonylurea	tablet
glyburide/metformin	Antidiabetic	Sulfonylureas/Biguanides	tablet
glycopyrrolate	Respiratory	Anticholinergic	tablet, oral liquid
hepatitis A adult vaccine	Vaccines	Viral vaccine	injection
hepatitis A/B vaccine	Vaccines	Viral vaccine	injection
hepatitis B adult vaccine	Vaccines	Viral vaccine	injection
hepatitis B vaccine (recombinant, adjuvanted)	Vaccines	Viral vaccine	injection
human papilloma virus vaccine (recombinant)	Vaccines	Viral vaccine	injection
hydralazine	Cardiovascular	Vasodilating agents	tablet
hydrochlorothiazide	Cardiovascular	Thiazide diuretic	capsule, tablet
hydrocortisone	Anti-inflammatory	Corticosteroid	topical, tablet, enema
hydrocortisone/neomycin/polymyxin b	Anti-inflammatory/anti-infective	Corticosteroid/antibacterial	ear drops
hydrocortisone/pramoxine	Anti-inflammatory/anesthetic	Corticosteroid/anesthetic	topical
hydroxyzine	Respiratory or CNS	Antihistamine or anxiolytic	capsule, tablet, oral liquid
hyoscyamine	Gastrointestinal	Antispasmodic	tablet oral liquid
ibuprofen	Analgesic	Nonsteroidal anti-inflammatory drug	capsule, tablet, oral liquid
imiquimod	Dermatologic	Immune response modifier	topical
influenza vaccine (including high dose)	Vaccines	Viral vaccine	injection
inhaler spacer (one time only)	Respiratory	Inhaler spacer device	spacer device
insulin aspart	Antidiabetic	Insulin-rapid acting	injection
insulin degludec	Antidiabetic	Insulin	injection
insulin detemir	Antidiabetic	Insulin intermediate to long acting	injection
insulin glargine	Antidiabetic	Insulin-long acting	injection
insulin isophane (NPH)	Antidiabetic	Insulin-intermediate acting	injection
insulin lispro	Antidiabetic	Insulin-rapid acting	injection
insulin NPH and insulin regular	Antidiabetic	Insulin-70/30	injection
insulin regular	Antidiabetic	Insulin-short acting	injection
ipratropium	Respiratory	Anticholinergic	inhaler, nebulizer solution
irbesartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
irbesartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
isoniazid	Anti-infective	Antimycobacterial	tablet, oral liquid
isosorbide dinitrate	Cardiovascular	Vasodilating agents	tablet
isosorbide mononitrate	Cardiovascular	Vasodilating agents	tablet
itraconazole	Anti-infective	Azole antifungal	capsule, oral liquid
ivabradine	Cardiovascular	Hyperpolarization-activated cyclic nucleotide-gated channel blocker	tablet, oral liquid
ketoconazole	Anti-infective	Azole antifungal	tablet, topical
labetalol	Cardiovascular	Beta-blocker	tablet
lactulose	Gastrointestinal	Laxative, osmotic	oral liquid
lamotrigine	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
lanolin alcohol-mo-w.pet-ceres (Eucerin)	Emollient	Moisturizer	topical
lansoprazole	Gastrointestinal	Proton pump inhibitor	capsule, tablet
lanthanum carbonate	Gastrointestinal	Phosphate binder	tablet

## Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
<a href="#">latanoprost</a>	Antiglaucoma	Prostaglandin	eye drops
<a href="#">ledipasvir/sofosbuvir</a>	Anti-infective	Hepatitis C antiviral	tablets, oral pellet packet
<a href="#">leucovorin</a>	Vitamin	Vitamin	tablet
<a href="#">levetiracetam</a>	Central nervous system	Anticonvulsant, mood stabilizer	tablet, oral liquid
<a href="#">levofloxacin</a>	Anti-infective	Quinolone antibiotic	tablet, oral liquid
<a href="#">levonorgestrel</a>	Endocrine	Progestin	tablet, intrauterine device
<a href="#">levothyroxine</a>	Endocrine	Thyroid supplement	tablet
<a href="#">lidocaine</a>	Anesthetic	Anesthetic	topical
<a href="#">linaclootide</a>	Gastrointestinal	Irritable bowel syndrome agent	capsule
<a href="#">liothyronine</a>	Endocrine	Thyroid supplement	tablet
<a href="#">liraglutide</a>	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	injection
<a href="#">lisinopril</a>	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor	tablet
<a href="#">lisinopril/hydrochlorothiazide</a>	Cardiovascular	Angiotensin converting enzyme (ACE) inhibitor/ thiazide	tablet
<a href="#">lithium carbonate</a>	Central nervous system	Mood stabilizer	capsule, tablet
<a href="#">loperamide</a>	Gastrointestinal, antidiarrheal	Antidiarrheal	capsule, tablet, oral liquid
<a href="#">loratadine</a>	Respiratory	Antihistamine	capsule, tablet, oral liquid
<a href="#">lorazepam<sup>CS</sup></a>	Central nervous system	Benzodiazepine	tablet, oral liquid
<a href="#">losartan</a>	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet
<a href="#">losartan/hydrochlorothiazide</a>	Cardiovascular	ARB/ thiazide diuretic	tablet
<a href="#">loteprednol etabonate</a>	Ophthalmic	Corticosteroid	eye drops, eye gel
<a href="#">lurasidone</a>	Central nervous system	Antipsychotic, atypical	tablet
<a href="#">magnesium oxide</a>	Vitamin	Vitamin	capsule tablet
<a href="#">measles, mumps, rubella vaccine</a>	Vaccines	Viral vaccine	injection
<a href="#">meclizine</a>	Central nervous system	Antivertigo, antiemetic	tablet
<a href="#">medroxyprogesterone</a>	Endocrine	Progestin	tablet, injection
<a href="#">megestrol</a>	Gastrointestinal, appetite stimulant	Endocrine, progestin	tablet, oral liquid
<a href="#">meloxicam</a>	Analgesic	Non-steroidal anti-inflammatory drug	capsule, tablet
<a href="#">meningococcal conjugate vaccine</a>	Vaccines	Bacterial vaccine	injection
<a href="#">mesalamine</a>	Gastrointestinal	5-Aminosalicylate	capsule, tablet, enema, rectal suppository
<a href="#">metformin</a>	Antidiabetic	Biguanide	tablet
<a href="#">metformin/sitagliptin</a>	Antidiabetic	Biguanide/DPP-4 inhibitor	tablet
<a href="#">methylcellulose</a>	Gastrointestinal	Laxative, bulk-forming	oral powder, tablet
<a href="#">methylprednisolone</a>	Endocrine	Glucocorticoid	tablet
<a href="#">metoclopramide</a>	Gastrointestinal	Antiemetic, prokinetic	tablet, oral liquid, nasal spray
<a href="#">metoprolol succinate</a>	Cardiovascular	Beta-blocker	capsule, tablet
<a href="#">metoprolol tartrate</a>	Cardiovascular	Beta-blocker	tablet
<a href="#">metoprolol tartrate/hydrochlorothiazide</a>	Cardiovascular	Beta-blocker/thiazide diuretic	tablet
<a href="#">metronidazole</a>	Anti-infective	Amebicide, trichomonaside	capsule, tablet, topical
<a href="#">midodrine</a>	Cardiovascular	Vasopressor	tablet
<a href="#">mirtazapine</a>	Central nervous system	Tetracyclic antidepressant	tablet
<a href="#">modafinil<sup>CS</sup></a>	Central nervous system	Stimulant	tablet
<a href="#">mometasone</a>	Respiratory or Dermatologic	Corticosteroid	inhaler, nasal spray, topical

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
<a href="#">mometasone/formoterol</a>	Respiratory	Corticosteroid/long-acting Beta-2 agonist	inhaler
<a href="#">mometasone/olopatadine</a>	Respiratory	Corticosteroid/antihistamine	nasal spray
<a href="#">montelukast</a>	Respiratory	Leukotriene receptor antagonist	tablet, oral granules
<a href="#">moxifloxacin</a>	Anti-infective	Quinolone antibiotic	tablet, eye drops
<a href="#">multivitamin</a>	Vitamin	Vitamin	tablet
<a href="#">multivitamin prenatal</a>	Vitamin	Vitamin	tablet
<a href="#">multivitamin with minerals</a>	Vitamin	Vitamin	tablet
<a href="#">mupirocin</a>	Dermatologic	Antibiotic	topical
<a href="#">naloxone</a>	Substance abuse	Opiate antagonist	nasal spray, injection
<a href="#">naltrexone</a>	Substance abuse	Opiate antagonist	capsule, tablet, injection
<a href="#">naltrexone ER/bupropion ER</a>	Anti-obesity	Anorectic agents	tablet
<a href="#">naproxen</a>	Analgesic	Nonsteroidal anti-inflammatory drug	tablet, oral liquid
<a href="#">naratriptan</a>	Central nervous system	Antimigraine	tablet
<a href="#">nepafenac</a>	Anti-inflammatory	Non-steroidal anti-inflammatory drug	eye drops
<a href="#">niacin</a>	Cardiovascular, antihyperlipidemic	Vitamin, lipotropic	capsule, tablet
<a href="#">nicotine</a>	Substance abuse	Nicotine replacement	gum, inhaler, lozenge, nasal spray, patch
<a href="#">nifedipine</a>	Cardiovascular	Calcium channel blocker	capsule, tablet
<a href="#">nitrofurantoin</a>	Anti-infective	Nitrofuan derivative	capsule, oral liquid
<a href="#">nitroglycerin</a>	Cardiovascular	Vasodilating agents	capsule, nasal spray, tablet, topical
<a href="#">norethindrone</a>	Endocrine	Progestin	tablet
<a href="#">nortriptyline</a>	Central nervous system, antidepressant	Tricyclic antidepressant (TCA)	capsule, oral liquid
<a href="#">nystatin</a>	Anti-infective	Antifungal	tablet, oral liquid, topical
<a href="#">olanzapine</a>	Central nervous system	Antipsychotic, antimanic	tablet, injection
<a href="#">olmesartan</a>	Cardiovascular	Angiotensin II receptor blocker	tablet
<a href="#">olmesartan/hydrochlorothiazide</a>	Cardiovascular	ARB/ thiazide diuretic	tablet
<a href="#">olopatadine</a>	Respiratory	Anti-histamine	eye drops, nasal spray
<a href="#">omega 3 (icosapent ethyl)</a>	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
<a href="#">omega-3-acid ethyl esters</a>	Cardiovascular, antihyperlipidemic	Lipotropic	capsule
<a href="#">omeprazole</a>	Gastrointestinal, acid reducing	Proton pump inhibitor	capsule, tablet, oral liquid
<a href="#">ondansetron</a>	Central nervous system	Anti-nausea	tablet, oral film
<a href="#">orlistat</a>	Anti-obesity	Gastrointestinal lipase inhibitor	capsule
<a href="#">oseltamivir</a>	Anti-infective	Anti-influenza antiviral	capsule, oral liquid
<a href="#">oxybutynin</a>	Genitourinary	Bladder antispasmodic	tablet, oral liquid, topical
<a href="#">oxycodone<sup>CS</sup></a>	Analgesic	Opiate	capsule, tablet, oral liquid
<a href="#">pancrelipase (amylase, lipase, protease)</a>	Gastrointestinal	Pancreatic enzyme replacement	capsule, tablet
<a href="#">pantoprazole</a>	Gastrointestinal, acid reducing	Proton pump inhibitor	tablet, oral granules, oral liquid
<a href="#">paromomycin</a>	Anti-infective	Amebicide	capsule
<a href="#">paroxetine</a>	Central nervous system, antidepressant	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
<a href="#">penicillin</a>	Anti-infective	Beta-lactam antibiotic	tablet, oral liquid, injection
<a href="#">permethrin</a>	Dermatologic	Anti-infective, scabicide	topical
<a href="#">pioglitazone</a>	Antidiabetic	Thiazolidinedione (glitazone)	tablet
<a href="#">pitavastatin</a>	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet

## Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
pneumococcal 15-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 20-valent conjugate vaccine	Vaccines	Bacterial vaccine	injection
pneumococcal 23-polyvalent vaccine	Vaccines	Bacterial vaccine	injection
podofilox	Dermatologic	Antiviral	topical
polycarbophil	Gastrointestinal	Laxative, bulk-forming	tablet
polyethylene glycol and electrolytes	Gastrointestinal	Osmotic laxative	oral liquid
polyethylene glycol/propylene glycol	Ophthalmic	Lubricating agent	eye drops
polysaccharide-iron complex	Vitamin	Vitamin	capsule
potassium chloride	Cardiovascular	Electrolyte replacement	capsule, tablet, oral liquid
prasugrel	Cardiovascular	Platelet inhibitor	tablet
pravastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	tablet
prazosin	Cardiovascular	Anti-hypertensive, Alpha-blocker	capsule
prednisolone	Endocrine	Corticosteroid	tablet, oral liquid, eye drops
prednisone	Endocrine	Corticosteroid	tablet, oral liquid
pregabalin <sup>CS</sup>	Central nervous system	Anticonvulsant, mood stabilizer	capsule, tablet, oral liquid
primaquine	Anti-infective	Antimalarial	tablet
promethazine	Gastrointestinal	Antihistamine, antiemetic	tablet, oral liquid, rectal suppository
propranolol	Cardiovascular	Beta-blocker	tablet, capsule, oral liquid
psyllium	Gastrointestinal	Laxative, bulk-forming	capsule, oral powder
pyrazinamide	Anti-infective	Antimycobacterial	tablet
pyridoxine (vitamin B6)	Vitamin	Vitamin	capsule, tablet, oral liquid
pyrimethamine	Anti-infective	Antimalarial	tablet
quetiapine	Central nervous system	Antipsychotic, antimanic	tablet
respiratory syncytial virus (RSV) vaccine	Vaccines	Viral vaccine	injection
respiratory syncytial virus (RSV) vaccine, adjuvanted	Vaccines	Viral vaccine	injection
ribavirin	Anti-infective	Hepatitis C antiviral	capsule, tablet
rifabutin	Anti-infective	Antimycobacterial	capsule
rifampin	Anti-infective	Antimycobacterial	capsule
rifapentine	Anti-infective	Antimycobacterial	tablet
rifaximin	Gastrointestinal	Anti-infective	tablet
risperidone	Central nervous system	Antipsychotic, atypical	tablet, oral liquid, injection
rivaroxaban	Blood formation and coagulation	Anticoagulant	tablet, oral liquid
rizatriptan	Central nervous system	Antimigraine	tablet
rosuvastatin	Cardiovascular, antihyperlipidemic	HMG-CoA reductase inhibitor	capsule, tablet
sacubitril/valsartan	Cardiovascular	Neprilysin inhibitor/ARB	tablet
SARS-CoV-2 (COVID 19) vaccine	Vaccines	Viral vaccine	injection
semaglutide	Antidiabetic	Glucagon-like peptide-1 receptor agonist (GLP-1 RA)	tablet, injection
sertraline	Central nervous system	Selective serotonin reuptake inhibitor (SSRI)	capsule, tablet, oral liquid
sildenafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
sitagliptin	Antidiabetic	Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor)	tablet
smallpox/monkeypox vaccine	Vaccines	Viral vaccine	injection
sofosbuvir/velpatasvir	Anti-infective	Hepatitis C antiviral	tablet, oral pellet packet

# Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*  
 CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
sofosbuvir/velpatasvir/voxilaprevir	Anti-infective	Hepatitis C antiviral	tablet
spironolactone	Cardiovascular	Potassium sparing diuretic	tablet, oral liquid
spironolactone/hydrochlorothiazide	Cardiovascular	Potassium sparing diuretic combinations	tablet
sucralfate	Gastrointestinal	Gastric acid buffer	tablet, oral liquid, mucosal paste
sulfadiazine	Anti-infective	Sulfonamide antibiotic	tablet
sulfamethoxazole/trimethoprim	Anti-infective	Sulfonamide antibiotic	tablet, oral liquid
sumatriptan	Central nervous system	Antimigraine	tablet, injection, nasal spray
tadalafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet, oral liquid
tamsulosin	Genitourinary	Alpha-blocker	capsule
terazosin	Cardiovascular	Alpha-blocker	capsule
terconazole	Anti-infective	Azole antifungal	topical, vaginal suppository
testosterone <sup>CS</sup>	Endocrine	Androgen	injection, gel, patch ( <i>note: testosterone undecanoate is nonformulary</i> )
tetanus diphtheria (Td) vaccine	Vaccines	Bacterial vaccine	injection
tetanus diphtheria-acellular pertussis (Tdap) vaccine	Vaccines	Bacterial vaccine	injection
timolol	Antiglaucoma	Beta blocker	eye drops, tablet
tinidazole	Anti-infective	Amebicide, trichomonoside	tablet
tiotropium	Respiratory	Anti-cholinergic, oral inhaled	inhaler
tiotropium/olodaterol	Respiratory	Long-acting muscarinic antagonist/long-acting Beta-2 agonist	inhaler
tizanidine	Central nervous system	Muscle relaxant	capsule, tablet
topiramate	Central nervous system	Anticonvulsant	capsule, tablet, oral liquid
tramadol <sup>CS</sup>	Analgesic	Opioid	capsule, tablet, oral liquid
travoprost	Antiglaucoma	Prostaglandin	eye drops
trazodone	Central nervous system, antidepressant	Serotonin reuptake inhibitor	tablet
tretinoin	Dermatologic	Anti-acne retinoid	capsule, topical
triamcinolone	Respiratory or Dermatologic	Corticosteroid	nasal spray, topical, oral paste
triamcinolone/nystatin	Dermatologic	Corticosteroid/antifungal	topical
triamterene/hydrochlorothiazide	Cardiovascular	Potassium sparing/thiazide diuretic	capsule
umeclidinium	Respiratory	Anticholinergic	inhaler
umeclidinium/vilanterol	Respiratory	Anticholinergic/long-acting Beta-2 agonist	inhaler
valacyclovir	Anti-infective	Antiherpetic antiviral	tablet
valganciclovir	Anti-infective	Antiherpetic antiviral (CMV)	tablet
valproic acid	Central nervous system	Anticonvulsant, mood stabilizer	capsule, oral liquid
valsartan	Cardiovascular	Angiotensin II receptor blocker (ARB)	tablet, oral liquid
valsartan/hydrochlorothiazide	Cardiovascular	ARB/ thiazide diuretic	tablet
vancomycin	Anti-infective	Glycopeptide antibiotic	capsule, oral liquid
vardenafil	Genitourinary	Phosphodiesterase type 5 inhibitor	tablet
varenicline	Smoking cessation	Partial nicotine agonist	tablet, nasal spray
venlafaxine	Central nervous system, antidepressant	Serotonin-norepinephrine reuptake inhibitor	capsule, tablet
verapamil	Cardiovascular	Calcium channel blocker	capsule, tablet
vitamin B complex	Vitamin	Vitamin	capsule, tablet
vitamin C	Vitamin	Vitamin	tablet

## Florida AIDS Drug Assistance Program (ADAP) Formulary   September 2024

\*\*\*\*Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.\*\*\*\*

CS indicates controlled substance. PA indicates prior authorization required.

Generic Name	Therapeutic Classification	Pharmacologic Classification	Dosage Forms
voriconazole	Anti-infective	Azole antifungal	tablet, oral liquid
warfarin	Blood formation and coagulation	Vitamin K antagonist	tablet
ziprasidone	Central nervous system	Antipsychotic, atypical	capsule, injection
zolpidem <sup>CS</sup>	Central nervous system	Sedative-hypnotic	capsule, tablet
zoster vaccine (recombinant)	Vaccines	Viral vaccine	injection